Summary
Somatostatin treatment was administered to 20 psoriatic patients according to the following protocol: Continuous infusion (250 μg/h) for at least 2 days followed either by short infusions (1 h) at 8 A.M. and 8 P.M. (12 cases) or by repeating the initial 2-day infusion (eight patients). Before treatment (day 0) and on day 6, biopsy specimens were taken for routine examination (12 patients) and for ultrastructure (seven patients). In vitro immunological studies were carried out on peripheral blood lymphocytes (six patients) on day 0 and day 8.
In two patients, somatostatin was stopped because of serious side effects. Thus, clinical results were evaluated in 18 patients, on day 30. In ten of them no improvement whatsoever occurred, two had a partial clearing and an almost complete remission was achieved in six others. Ultrastructural studies showed, on day 6, enlargement of the intercellular spaces with deposits of granular material of glucidic composition, associated with features of cellular damage. Percentages of T and B cells were unmodified but a significant depression of mitogenic stimulation by PHA and ConA was clearly observed on day 8. Even if somatostatin treatment may have a beneficial effect in some patients it seems much less valid than other well-known therapies for psoriasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clot J, Dardenne M, Brochier J, Andary M, Guilhou JJ (1978) Evaluation of lymphocyte subpopulations and T cell functions in psoriasis. Clin Immunol Immunopathol 9:389–397
Diaz J, Guegan R, Beaumont M, Benoit J, Clement J, Fauchard C, Galtier D, Millan J, Muneaux C, Muneaux Y, Vedel M, Schwyzer R (1979) A large-scale synthesis of somatostatin for clinical use by a novel alternating solution/solid-phase procedure. Bioorganic Chemistry 8:429–442
Guilhou JJ, Guilhou E (1982) Bromocriptin treatment of psoriasis. Arch Dermatol Res 273:159–160
Guilhou JJ, Meynadier J, Clot J, Charmasson E, Dardenne M, Brochier J (1976) Immunological aspects of psoriasis. II. Dissociated impairment of thymus-dependent lymphocytes. Br J Dermatol 95:291–301
Guilhou JJ, Meynadier J, Clot J (1978) New concepts in the pathogenesis of psoriasis. Br J Dermatol 98:585–592
Hopsu-Havu VK, Niinikoski A, Haapalahti JE (1973) Serum insulin and growth hormone response to arginine infusion in healthy and psoriatic persons. Dermatologica 146:205–210
Kobberling J, von Werder K (1981) Psoriasis and human growth hormone. Arch Dermatol Res 271:463–464
Mc Quillan MT (ed) (1977) Somatostatin. In: Livingstone Ch (ed) Annual research reviews. Eden Press, Edinburgh, pp 91–104
Reynolds F (1963) The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J Cell Biol 17:208–211
Schultz-Ehrenburg U, Orfanos C (1981) Light and electron microscopic changes of human epidermis with oral retinoid treatment. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper C, Polano MK, Schuppli R (eds) Retinoids. Springer, Heidelberg, pp 85–92
Thiery JP (1967) Mise en évidence de polysaccharides sur coupes fines en microscopie électronique. J Microscopie 6:987–1018
Weber G, Klughardt G, Neidehardt M (1981) Psoriasis and human growth hormone: Aetiology and therapy. Arch Dermatol Res 270:361–365
Weber G, Neighardt M, Frey H, Galle K, Geiger A (1981) Treatment of psoriasis with bromocriptin. Arch Dermatol Res 271:437–439
Weber G, Neighardt M, Schmidt A, Geiger A (1981) Korrelation von Wachstumshormonen und klinischen Bild der Psoriasis. Arch Dermatol Res 270:129–140
Weber G, Krughardt G, Neidhardt M, Galle K, Frey H, Geiger A (1982) Treatment of psoriasis with somatostatin. Arch Dermatol Res 272:31–36
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guilhou, J.J., Boulanger, A., Barneon, G. et al. Somatostatin treatment of psoriasis. Arch Dermatol Res 274, 249–257 (1982). https://doi.org/10.1007/BF00403727
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00403727